Literature DB >> 2906101

The effect of a selective phosphodiesterase inhibitor, rolipram, on muricide in olfactory bulbectomized rats.

T Mizokawa1, K Kimura, Y Ikoma, K Hara, N Oshino, T Yamamoto, S Ueki.   

Abstract

In order to evaluate the potential usefulness of the drug as an antidepressant, acute and chronic effects of rolipram, a selective inhibitor of Ca2+- and calmodulin-independent cyclic AMP phosphodiesterase were investigated on muricide in olfactory bulbectomized (OB) rats. Upon single administration to OB rats, rolipram at a dosage of 1 mg/kg body weight suppressed the muricide for 2 hr after its administration. As a consequence of daily administration of rolipram, however, the incidence of muricide at 24 hr after the administration was decreased, and more than 60% of the rats did not exhibit the muricide on the 12th day. After the cessation of the administration, the incidence of the muricide returned to the initial level. The suppression of the muricide was not antagonized by several kinds of neurotransmitter blockers. Administrations of phosphodiesterase inhibitors and dibutyryl cyclic AMP as well as desipramine and clomipramine also suppressed the muricide dose-dependently. Repeated administration of desipramine also gave results similar to those of rolipram: repetition of a short suppression on the muricide was followed by the appearance of a long-lasting suppression. Differently from rolipram and desipramine, dibutyryl cyclic AMP did not cause long-lasting suppression, and even the direct effect (75% suppression) observed 30 min after its administration on the first day disappeared during its repeated administration for 14 days. From these results, rolipram was considered to show an antidepressant effect through the inhibition of Ca2+- and calmodulin-independent cyclic AMP phosphodiesterase.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2906101     DOI: 10.1254/jjp.48.357

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  6 in total

1.  Effects of the phosphodiesterase inhibitor rolipram on the acoustic startle response in rats.

Authors:  J H Kehne; N M Boulis; M Davis
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

2.  Phosphodiesterase 4 inhibitors enhance sexual pleasure-seeking activity in rodents.

Authors:  Peixiong Yuan; Tyson Tragon; Menghang Xia; Christopher A Leclair; Amanda P Skoumbourdis; Wei Zheng; Craig J Thomas; Ruili Huang; Christopher P Austin; Guang Chen; Xavier Guitart
Journal:  Pharmacol Biochem Behav       Date:  2011-02-04       Impact factor: 3.533

3.  Attenuation of ethanol abstinence-induced anxiety- and depressive-like behavior by the phosphodiesterase-4 inhibitor rolipram in rodents.

Authors:  Mei-Fang Gong; Rui-Ting Wen; Ying Xu; Jian-Chun Pan; Ning Fei; Yan-Meng Zhou; Jiang-Ping Xu; Jian-Hui Liang; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2017-07-27       Impact factor: 4.530

Review 4.  The role of phosphodiesterases in schizophrenia : therapeutic implications.

Authors:  Judith A Siuciak
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.

Authors:  Judith A Siuciak; Sheryl A McCarthy; Douglas S Chapin; Ashley N Martin
Journal:  Psychopharmacology (Berl)       Date:  2007-12-01       Impact factor: 4.530

6.  Whole-body biodistribution and radiation dosimetry in monkeys and humans of the phosphodiesterase 4 radioligand [(11)C](R)-rolipram: comparison of two-dimensional planar, bisected and quadrisected image analyses.

Authors:  David R Sprague; Masahiro Fujita; Yong Hoon Ryu; Jeih-San Liow; Victor W Pike; Robert B Innis
Journal:  Nucl Med Biol       Date:  2008-05       Impact factor: 2.408

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.